 SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Companys mission to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. We are committed to developing superior vaccines that provide broader protection than what is available currently and to developing novel vaccines that target pathogens for which no approved vaccines exist, said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. 